SmurfVA's Random Picks

[Ned Serious]

DARA $.79 Pre-market : DARA Moving in Premarket, this time with Volume too. I believe this is what is making it move:

link here for full article : http://finance.yahoo.com/news/dara-biosciences-signs-pharmacy-supply-130500006.html

DARA BioSciences, Inc. (DARA), an oncology supportive care specialty pharmaceutical company dedicated to providing healthcare professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatments, announced that it has signed a pharmacy supply agreement with RainTree Oncology Services. This agreement is for both Gelclair®, an FDA-approved bioadherent oral rinse gel for treating the painful symptoms of oral mucositis (OM), and Soltamox® (tamoxifen citrate) oral liquid solution, to be accessible to RainTree's Nationwide Oncology Membership.

As the nation's leading community oncology alliance, RainTree Oncology Services assists its member practices in providing effective treatments to oncology patients, while developing commercial relationships that accelerate innovative oncology treatments and payer arrangements optimizing oncology patient care and advancing the practice of oncology. This agreement with RainTree Oncology Services gives RainTree member practices access to DARA's products. RainTree and DARA will work to provide both products to the RainTree nationwide oncology membership, many of which have in-house pharmaceutical dispensing services.

"We believe Gelclair and Soltamox address important therapeutic needs for thousands of patients treated by RainTree member practices and present a new opportunity to service the needs of patients suffering from cancer and cancer treatment side effects directly at the point of care. We are excited with the opportunity to offer product access to RainTree's member practices for both Soltamox and Gelclair and the opportunity to collaborate with them on this front. We view these types of strategic relationships as an integral component to our commercial success," stated David J. Drutz, M.D., DARA BioSciences' Chief Executive Officer and Chief Medical Officer.

Christopher Clement, DARA's President and Chief Operating Officer, commented, "Following the recent signing of our two-year exclusive agreement with Memorial Sloan Kettering for formulary access for Gelclair, we continue to work closely with other oncology market leaders in pursuit of additional agreements to optimize the utilization of our product portfolio. These relationships, in concert with the launch of our newly instituted 20 person national sales force earlier this month, are important drivers for what we anticipate to be an exciting 2014 for DARA."